Tempus AI (NASDAQ:TEM) Given New $70.00 Price Target at Morgan Stanley

Tempus AI (NASDAQ:TEM) had its price objective reduced by analysts at Morgan Stanley from $85.00 to $70.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 36.59% from the company’s current price.

A number of other research analysts have also weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Mizuho assumed coverage on Tempus AI in a report on Thursday, February 19th. They set an “outperform” rating and a $100.00 target price for the company. BTIG Research decreased their price objective on Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Robert W. Baird assumed coverage on Tempus AI in a research report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price objective on the stock. Finally, Stifel Nicolaus set a $60.00 price objective on Tempus AI in a research note on Wednesday, February 25th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.15.

Tempus AI Price Performance

NASDAQ TEM traded down $2.06 during trading hours on Tuesday, reaching $51.25. The company’s stock had a trading volume of 4,384,085 shares, compared to its average volume of 5,798,926. The firm has a market capitalization of $9.12 billion, a price-to-earnings ratio of -36.35 and a beta of 5.29. Tempus AI has a 1-year low of $36.22 and a 1-year high of $104.32. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The company’s 50-day moving average is $61.09 and its two-hundred day moving average is $73.22.

Insider Buying and Selling at Tempus AI

In related news, CEO Ryan Fukushima sold 9,592 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $566,407.60. Following the sale, the chief executive officer directly owned 694,354 shares in the company, valued at approximately $41,001,603.70. This represents a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Andrew Polovin sold 10,949 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $60.31, for a total transaction of $660,334.19. Following the completion of the sale, the executive vice president directly owned 126,918 shares in the company, valued at approximately $7,654,424.58. This trade represents a 7.94% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 590,109 shares of company stock valued at $37,056,566. Insiders own 26.27% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

A number of large investors have recently modified their holdings of the company. Renaissance Capital LLC raised its position in shares of Tempus AI by 26.9% during the 3rd quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock worth $6,793,000 after acquiring an additional 17,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Tempus AI by 1,459.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock worth $8,174,000 after purchasing an additional 94,783 shares in the last quarter. Hussman Strategic Advisors Inc. purchased a new stake in shares of Tempus AI during the 3rd quarter worth approximately $1,695,000. Vanguard Group Inc. boosted its holdings in shares of Tempus AI by 22.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after buying an additional 1,706,837 shares in the last quarter. Finally, Krane Funds Advisors LLC grew its position in shares of Tempus AI by 218.2% in the 3rd quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after buying an additional 19,358 shares during the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.